Research programme: antibody therapeutics - AP Biosciences

Drug Profile

Research programme: antibody therapeutics - AP Biosciences

Alternative Names: AP 105; AP 116; AP 117; AP 118; AP 119; AP 120; AP 201; AP 505

Latest Information Update: 22 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AP Biosciences
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Checkpoint kinase inhibitors; Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 22 Aug 2017 Research programme: antibody therapeutics - AP Biosciences is available for licensing as of 22 Aug 2017. http://www.apbioinc.com/english/about/about.php
  • 03 Aug 2017 Preclinical trials in Cancer in Taiwan (unspecified route) (AP Biosciences pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top